Literature DB >> 11981104

Fibrinolytic variables in postmenopausal women with unstable coronary artery disease.

N E Nielsen1, E Logander, E Swahn.   

Abstract

OBJECTIVES: Many women with typical anginal chest pain have normal coronary angiograms. The pathogenetic mechanisms behind the chest pain in these patients is unknown but may be due to altered fibrinolytic function enhancing thrombosis formation. We evaluated the two key components of the fibrinolytic system, tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in women with clinical signs of unstable coronary artery disease (CAD). METHODS AND
RESULTS: 158 patients with unstable CAD and 101 controls were examined. Of the patients 16% had normal vessels and 84% coronary atherosclerosis at coronary angiography. Mean plasma concentration of t-PA-ag, but not of PAI-1-act was higher in patients than in controls (t-PA-ag: 2.12 (2.05;2.19) vs. 1.98 (1.89;2.07), p<0.05; PAI-1-act: 1.55 (1.35;1.74) vs. 1.49 (1.24;1.73), p=n.s.). Patients with coronary atherosclerosis had significantly higher mean plasma levels of both t-PA-ag and PAI-1-act than patients with normal coronary vessels (t-PA-ag: 2.16 (2.08;2.33) vs. 1.94 (1.78;2.10), p<0.05; PAI-1-act: 1.68 (1.47;1.90) vs. 0.82 (0.43;1.21), p<0.01), and these differences were seen whether markers of myocardial damage were elevated or not. Mean plasma levels of PAI-1-act in patients with normal coronary vessels were even lower than in the control group (p<0.05). Almost all significant differences in mean plasma t-PA-ag and PAI-1-act disappeared after adjustments for known covariates.
CONCLUSION: Our results indicate, regardless of myocardial marker elevation or not, an activated fibrinolytic system in postmenopausal women with unstable CAD and coronary atherosclerosis, but not in the same group of patients with normal coronary vessels. This argues against reduced fibrinolytic capacity in the latter patients and therefore against thrombosis formation as the cause of chest pain in these women. However, we cannot exclude that the differences can be an effect of inequality among some common risk factors between the groups.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11981104     DOI: 10.1023/a:1015270907430

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  18 in total

Review 1.  Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology.

Authors: 
Journal:  Eur Heart J       Date:  1997-03       Impact factor: 29.983

2.  Percutaneous interventions alter the hemostatic profile of patients with unstable versus stable angina.

Authors:  S Yazdani; A D Simon; L Kovar; W Wang; A Schwartz; L E Rabbani
Journal:  J Am Coll Cardiol       Date:  1997-11-01       Impact factor: 24.094

3.  Markers of hypercoagulation and von Willebrand factor in postmenopausal women with unstable coronary artery disease. Discriminatory ability regarding unstable coronary artery disease and coronary atherosclerosis using receiver operating characteristics.

Authors:  N E Nielsen; A Siegbahn; E Swahn
Journal:  J Intern Med       Date:  2000-08       Impact factor: 8.989

Review 4.  Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes.

Authors:  J Fareed; D A Hoppensteadt; F Leya; O Iqbal; H Wolf; R Bick
Journal:  Clin Chem       Date:  1998-08       Impact factor: 8.327

5.  Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study.

Authors:  O C Gebara; M A Mittleman; P Sutherland; I Lipinska; T Matheney; P Xu; F K Welty; P W Wilson; D Levy; J E Muller
Journal:  Circulation       Date:  1995-04-01       Impact factor: 29.690

6.  Plasminogen activator inhibitor activity as a possible indicator of disease activity in rest angina with angiographically insignificant coronary artery stenosis.

Authors:  K Sakata; C Kurata; A Kobayashi; A Rydzewski; N Yamazaki
Journal:  Thromb Res       Date:  1991-09-01       Impact factor: 3.944

7.  Tissue-type plasminogen activator and plasminogen activator inhibitor activities as predictors of adverse events in unstable angina.

Authors:  I Wieczorek; C A Ludlam; K A Fox
Journal:  Am J Cardiol       Date:  1994-09-01       Impact factor: 2.778

8.  Tissue plasminogen activator release and plasminogen activator inhibitor levels in coronary artery disease.

Authors:  D G Meyers; W D Haire; J K Rasmussen; E J Boyd
Journal:  Angiology       Date:  1991-07       Impact factor: 3.619

9.  Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.

Authors: 
Journal:  Lancet       Date:  1996-03-02       Impact factor: 79.321

10.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

Authors:  A Hamsten; B Wiman; U de Faire; M Blombäck
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.